HC Wainwright restated a “buy” rating and set a $24.00 price target on shares of Capricor Therapeutics in a research report on Thursday, September 25th. Get Capricor Therapeutics alerts:Get Our Latest Stock Report on CAPRCapricor Therapeutics Stock PerformanceShares of NASDAQ CAPR opened at $7.41 on Friday. Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%. Analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current year. Featured StoriesReceive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.